Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Bladder Cancer |
Free Subscription
1 ACS Appl Mater Interfaces |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Bladder Cancer is free of charge.
Urease-Powered Black TiO(2) Micromotors for Photothermal Therapy of Bladder
Cancer.
ACS Appl Mater Interfaces. 2024 Jan 13. doi: 10.1021/acsami.3c11772.
PubMed
Abstract available
Molecular Subtypes of Bladder Cancer: Component Signatures and Potential Value in
Clinical Decision-making.
Adv Anat Pathol. 2024 Jan 18. doi: 10.1097/PAP.0000000000000430.
PubMed
Abstract available
Molecular map of cGAS-STING pathway-related genes in bladder cancer: the
perspective toward immune microenvironment and prognosis.
Aging (Albany NY). 2024;15.
PubMed
Abstract available
Nadofaragene: a new era of precision medicine for bladder cancer.
Ann Med Surg (Lond). 2023;86:7-10.
PubMed
Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for
muscle-invasive bladder cancer: case series.
Ann Med Surg (Lond). 2023;86:245-251.
PubMed
Abstract available
Erdafitinib versus pembrolizumab in pretreated patients with advanced or
metastatic urothelial cancer with select FGFR alterations: cohort 2 of the
randomized phase III THOR trial.
Ann Oncol. 2024;35:107-117.
PubMed
Abstract available
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan
plus enfortumab vedotin for metastatic urothelial carcinoma.
Ann Oncol. 2024;35:91-97.
PubMed
Abstract available
Retracted: Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis.
Biomed Res Int. 2024;2024:9869348.
PubMed
Abstract available
Retracted: The Use of BT-ESD Technology under General Intravenous Anesthesia in
the Treatment of Nonmuscle Invasive Bladder Cancer and the Effect of PI3K/Akt
Signaling Pathway on Tumor Recurrence.
Biomed Res Int. 2024;2024:9815062.
PubMed
Abstract available
Continent diversion is losing its momentum: a nationwide trend analysis from
Germany 2005-2021.
BJU Int. 2024;133:154-157.
PubMed
Significant advances in chemotherapy for both urothelial and renal cancer.
BJU Int. 2024;133:122-123.
PubMed
Near-infrared spectroscopy as a novel method of ex vivo bladder cancer tissue
characterisation.
BJU Int. 2024 Jan 18. doi: 10.1111/bju.16226.
PubMed
Abstract available
Elevated serum CA199 levels in patients suffering type 2 diabetes vs. various
types of cancer.
BMC Endocr Disord. 2024;24:9.
PubMed
Abstract available
Vesical fungal bezoars on post-TURBT scar tissue causing obstruction and
mimicking urothelial carcinoma.
BMJ Case Rep. 2024;17:e257132.
PubMed
Abstract available
USP5 facilitates bladder cancer progression by stabilizing the c-Jun protein.
Cancer Cell Int. 2024;24:32.
PubMed
Abstract available
Cell fusion upregulates PD-L1 expression for evasion from immunosurveillance.
Cancer Gene Ther. 2024;31:158-173.
PubMed
Abstract available
Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on
bladder cancer cells.
Cancer Gene Ther. 2024 Jan 17. doi: 10.1038/s41417-024-00725.
PubMed
Abstract available
USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer.
Cell Death Dis. 2024;15:44.
PubMed
Abstract available
Extraperitonealization of the ileal conduit decreases the risk of parastomal
hernia: A single-center, randomized clinical trial.
Cell Rep Med. 2024;5:101343.
PubMed
Abstract available
Local solutions to shorten treatment delays in bladder cancer. Results of a
survey among CEJU authors.
Cent European J Urol. 2023;76:280-282.
PubMed
Guillain-Barre Syndrome following intravesical Bacillus Calmette-Guerin therapy
for bladder cancer: a rare and intriguing case report.
Cent European J Urol. 2023;76:311-314.
PubMed
Abstract available
Effect of herniarin on cell viability, cell cycle, and Erk protein levels in
different stages of bladder cancer cells.
Chem Biodivers. 2024 Jan 18:e202301645. doi: 10.1002/cbdv.202301645.
PubMed
Abstract available
Bladder Cancer and the Urinary Microbiome-New Insights and Future Directions: A
Review.
Clin Genitourin Cancer. 2024 Jan 9:S1558-7673(23)00281.
PubMed
Abstract available
Snai2-mediated upregulation of NADSYN1 promotes bladder cancer progression by
interacting with PHB.
Clin Transl Med. 2024;14:e1555.
PubMed
Exosomal noncoding RNAs as noninvasive biomarkers in bladder cancer: a diagnostic
meta-analysis.
Clin Transl Oncol. 2024 Jan 16. doi: 10.1007/s12094-023-03374.
PubMed
Abstract available
Unraveling Bacillus Calmette-Guerin (BCG) Therapy Side Effects in Bladder Cancer:
A Tale of Triumph Over Treatment Challenges.
Cureus. 2023;15:e50498.
PubMed
Abstract available
Comparative Outcomes of Radical Cystectomy in Muscle-Invasive Bladder Cancer: A
Systematic Review and Meta-Analysis.
Cureus. 2023;15:e50646.
PubMed
Abstract available
Matched analysis of detailed peripheral blood and tumor immune microenvironment
profiles in bladder cancer.
Epigenomics. 2024;16:41-56.
PubMed
Abstract available
Stentless florence robotic intracorporeal neobladder (FloRIN), a feasibility
prospective randomized clinical trial.
Eur J Surg Oncol. 2024;50:107259.
PubMed
Abstract available
Urinary microbiota signatures associated with different types of urinary
diversion: a comparative study.
Front Cell Infect Microbiol. 2024;13:1302870.
PubMed
Abstract available
Determination of the Roles of Endothelial Nitric Oxide Synthase 4VNTR (4a/b),
G894T, T786C Gene Variations in the Bladder Cancer Development.
Indian J Clin Biochem. 2024;39:92-100.
PubMed
Abstract available
Regarding the role of HER2 overexpression on the survival in muscle-invasive
bladder cancer.
Int J Surg. 2024 Jan 18. doi: 10.1097/JS9.0000000000001091.
PubMed
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer
by abrogating immunosuppression.
J Clin Invest. 2024;134:e169241.
PubMed
Abstract available
Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells
reveals the FASN gene as a therapeutic for bladder cancer.
J Transl Med. 2024;22:55.
PubMed
Abstract available
Urinary Bladder Cancer Induced by N-Butyl-N-(4-Hydroxybutyl)-Nitrosamine.
Methods Mol Biol. 2024;2773:25-32.
PubMed
Abstract available
Establishment of Mouse Orthotopic Urinary Bladder Tumor Model and Its Analysis by
Light and Electron Microscopy.
Methods Mol Biol. 2024;2773:33-49.
PubMed
Abstract available
circRNA TATA-box binding protein associated factor 15 acts as an oncogene to
facilitate bladder cancer progression through targeting miR-502-5p/high mobility
group box 3.
Mol Carcinog. 2024 Jan 16. doi: 10.1002/mc.23677.
PubMed
Abstract available
KLHDC7B as a novel diagnostic biomarker in urine exosomal mRNA promotes bladder
urothelial carcinoma cell proliferation and migration, inhibits apoptosis.
Mol Carcinog. 2024;63:286-300.
PubMed
Abstract available
How Do Molecular Classifications Affect the Neoadjuvant Treatment of
Muscle-Invasive Urothelial Carcinoma?
Mol Diagn Ther. 2024;28:37-51.
PubMed
Abstract available
Urease-powered nanobots for radionuclide bladder cancer therapy.
Nat Nanotechnol. 2024 Jan 15. doi: 10.1038/s41565-023-01577.
PubMed
Abstract available
Urinoids - a new tool to study bladder cancer.
Nat Rev Urol. 2024 Jan 16. doi: 10.1038/s41585-024-00853.
PubMed
Naunyn Schmiedebergs Arch Pharmacol
Molecular mechanism of anticancer effect of heat shock protein 90 inhibitor
BIIB021 in human bladder cancer cell line.
Naunyn Schmiedebergs Arch Pharmacol. 2024.
PubMed
Abstract available
Ubiquitin-specific protease 5 promotes bladder cancer progression through
stabilizing Twist1.
Oncogene. 2024 Jan 13. doi: 10.1038/s41388-023-02936.
PubMed
Abstract available
Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma
in Sweden between 2015 and 2021: a population-based survey.
Scand J Urol. 2024;59:19-25.
PubMed
Abstract available
Pathological complete response to neoadjuvant chemotherapy may improve antitumor
immune response via reduction of regulatory T cells in muscle-invasive bladder
cancer.
Sci Rep. 2024;14:1442.
PubMed
Abstract available
Age related trends in the utilization of neoadjuvant chemotherapy for muscle
invasive bladder cancer.
Urol Oncol. 2024 Jan 17:S1078-1439(24)00007.
PubMed
Abstract available
Quality of Life in the Phase 2/3 Trial of N-803 Plus BCG in BCG-Unresponsive
Non-Muscle Invasive Bladder Cancer.
Urol Pract. 2024 Jan 16:101097UPJ0000000000000517.
PubMed
Abstract available
Zhejiang Da Xue Xue Bao Yi Xue Ban
Classification of bladder cancer based on immune cell infiltration and
construction of a risk prediction model for prognosis.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024.
PubMed
Abstract available
Thank you for your interest in scientific medicine.